These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3861233)

  • 1. Treatment of acute myelogenous leukemia in adults with N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Kimura K; Ohno R; Amaki I; Hattori K; Hirota Y; Hoshino A; Ichimaru M; Ito M; Kimura I; Maekawa T
    Cancer; 1985 Oct; 56(8):1913-7. PubMed ID: 3861233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
    Park HS; Kim DW; Kim CC; Kim HK; Kim JS; Hwang TJ; Kim HJ; Kim HS; Song HS; Park JW; Ahn HS; Chung TJ; Cho KS; Lee KS; Choi YM
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):24-9. PubMed ID: 8916313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Kimura K; Yamada K; Uzuka Y; Maekawa T; Takaku F; Shimoyama M; Ogawa M; Amaki I; Osamura S; Ito M; Sakai Y; Oguro M; Hattori K; Hoshino A; Hirota Y; Ohta K; Nakamura T; Masaoka T; Kimura I; Ichimaru M
    Recent Results Cancer Res; 1981; 76():232-40. PubMed ID: 7232852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea.
    Lee DH; Chung NG; Cho B; Kim HK; Kang HJ; Shin HY; Ahn HS; Yoo KH; Sung KW; Koo HH; Kook H; Hwang TJ; Im HJ; Seo JJ; Park HJ
    J Korean Med Sci; 2010 Jan; 25(1):9-15. PubMed ID: 20052341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Low-dose 4N-behenoyl-1-beta-D-arabinofuranosylcytosine (BHAC) in the treatment of atypical leukemia].
    Takahashi I; Nakada H; Hayashi N; Sekito N; Inagaki T; Aoyama S; Nonaka K; Ohmoto E; Kobayashi Y; Uchida K
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2780-5. PubMed ID: 3463249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behenoyl cytosine arabinoside, aclacinomycin A, 6-mercaptopurine, and prednisolone combination therapy for acute non-lymphocytic leukaemia in adults.
    Yoshida M; Suda K; Tsuboyama A; Sasaki R; Kitagawa S; Kano Y; Muto Y; Takaku F; Sakamoto S; Miura Y
    Eur J Haematol; 1989 Jul; 43(1):1-6. PubMed ID: 2767238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
    Yamauchi T; Kawai Y; Goto N; Kishi S; Imamura S; Yoshida A; Urasaki Y; Fukushima T; Iwasaki H; Tsutani H; Masada M; Ueda T
    Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.
    Ohno R; Kato Y; Nagura E; Murase T; Okumura M; Yamada H; Ogura M; Minami S; Suzuki H; Morishima Y
    J Clin Oncol; 1986 Dec; 4(12):1740-7. PubMed ID: 3465875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
    Kobayashi T; Miyawaki S; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Ohmoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Matsuoka A; Tomonaga M; Ohno R
    J Clin Oncol; 1996 Jan; 14(1):204-13. PubMed ID: 8558199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Kimura K; Ohno R; Amaki I; Hattori K; Hirota Y; Hoshino A; Ichimaru M; Ito M; Kimura I; Maekawa T
    Med Oncol Tumor Pharmacother; 1986; 3(1):15-24. PubMed ID: 3702507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aclarubicin plus behenoyl cytarabine and prednisolone for previously treated acute myeloid leukemia patients.
    Dobashi N; Asai O; Yano S; Osawa H; Takei Y; Yamaguchi Y; Saito T; Yamazaki H; Kobayashi T; Usui N
    Leuk Lymphoma; 2006 Oct; 47(10):2203-7. PubMed ID: 17071496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behenoyl cytarabine-associated reversible encephalopathy in a patient with acute myelogenous leukemia.
    Cho SG; Moon H; Lee JH; Lee SY; Kim CC; Lee KS
    J Korean Med Sci; 1999 Feb; 14(1):89-92. PubMed ID: 10102531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
    Yoshida M; Owada N; Sasaki R; Sakamoto S; Miura Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Early phase II study of PL-AC [N4-palmitoyl-(1-beta-D-arabinofuranosyl) cytosine] on hematopoietic malignancies].
    Takubo T; Kubota Y; Tanaka T; Ueda T; Shibata H; Nakamura H; Masaoka T; Yoshitake J; Ishigami S
    Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):283-9. PubMed ID: 6576729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
    Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
    Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo distribution of 14C-labeled N4-behenoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Toyoshima S; Fukuma M; Seto Y; Fujita H; Fukushima K; Tomioka H; Sakurai T; Sugimoto Y; Yagi T; Hoshino T; Sowa T
    Gan; 1981 Feb; 72(1):19-29. PubMed ID: 7274645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of myelodysplastic syndromes (MDS) with oral administration of N4-palmitoyl-1-beta-D-arabinofuranosyl cytosine (PLAC)].
    Ohno R; Kimura K
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1205-8. PubMed ID: 3382195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapeutic effects in hypoplastic leukemia].
    Takahashi I; Nakada H
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1209-14. PubMed ID: 3260089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
    Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma and leukemic cell pharmacokinetics of high-dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute leukemia patients.
    Yoshida T; Kobayashi K; Okabe Y; Okumura H; Matano S; Kanno M; Takeda Y; Ohtake S; Nakamura S; Matuda T
    J Clin Pharmacol; 1994 Jan; 34(1):52-9. PubMed ID: 8132852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.